Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD

Running, not enrolling · Phase 4

Conditions studied: Coronary Artery Disease

In brief

The Ischemia-IMT (Ischemia-Intensive Medical Treatment Reduces Events in Women with Non-Obstructive CAD), subtitle: Women's Ischemia Trial to Reduce Events in Non-Obstructive CAD (WARRIOR) trial is a multicenter, prospective, randomized, blinded outcome evaluation (PROBE design) evaluating intensive statin/ACE-I (or ARB)/aspirin treatment (IMT) vs. usual care (UC) in 4,422 symptomatic women patients with symptoms and/or signs of ischemia but no obstructive CAD. The hypothesis is that IMT will reduce major adverse coronary events (MACE) 20% vs. UC. The primary outcome is first occurrence of MACE as death, nonfatal MI, nonfatal stroke/transient ischemic attack (TIA) or hospitalization for heart failure or angina. Secondary outcomes include quality of life, time to "return to duty"/work, health resource consumption, angina, cardiovascular (CV) death and primary outcome components. Events will be adjudicated by an experienced Clinical Events Committee (CEC). Follow-up was planned to be 3-years using 50 sites: primarily VA and Active Duty Military Hospitals/Clinics and a National Patient-Centered Clinical Research Network (PCORnet) clinical data research network (CDRN)(OneFlorida Consortium). The number of sites were increased and follow up was modified to continue until the last patient enrolled was followed until trial follow up was completed. Recruitment was complete January 6, 2024. This study is being conducted to determine whether intensive medication treatment to modify risk factors and vascular function in women patients with coronary arteries showing no flow limit obstruction but with cardiac symptoms (i.e., chest pain, shortness of breath) will reduce the patient's likelihood of dying, having a heart attack, stroke/TIA or being hospitalized for cardiac reasons. The results will provide evidence data necessary to inform future guidelines regarding how best to treat this growing population of patients, and ultimately improve the patient's cardiac health and quality of life and reduce health-care costs.

Key facts

Study ID: NCT03417388
Run by: Cedars-Sinai Medical Center
People needed: 2476
Starts: 2018-02-09
Expected to finish: 2026-09-14
Last updated by the study team: 2026-05-29

Who can join

Age: 18 and older, up to 100. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

Signs and symptoms of suspected ischemia prompting referral for further evaluation by cardiac catheterization or coronary angiogram or coronary CT angiogram within 5 years from consent
Willing to provide written informed consent
Non-obstructive CAD defined as 0 to 49% diameter reduction of a major epicardial vessel or a FFR>0.80

You may not qualify if…

History of noncompliance (with medical therapy, protocol, or follow-up)
History of non-ischemic dilated or hypertrophic cardiomyopathy
Documented acute coronary syndrome(ACS) within previous 30 days
Left ventricular ejection fraction (LVEF) <40%, New York Heart Association heart failure (NYHA HF) class III-IV, or hospitalization for Reduced ejection fraction (HFrEF) within 180 days
Stroke within previous 180 days or intracranial hemorrhage at any time
End-stage renal disease, on dialysis, or estimated glomerular filtration rate (eGFR) <30 ml/min.
Severe valvular disease or likely to require surgery/Transcatheter aortic valve replacement (TVAR) within 3 years
Life expectancy <3-yrs. due to non-cardiovascular comorbidity
Enrolled in a competing clinical trial
Prior intolerance to both an ACE-I and ARB
If intolerant to a statin unless taking a PCSK9 as a statin replacement by their clinical provider
Pregnancy (all pre-menopausal females must have negative urine pregnancy test if randomized to IMT before study drugs are prescribed. If they have not gone through menopause, had a hysterectomy, oophorectomy, or sterilization such as tubal ligation procedure)

Where it is running

Dignity Health-Mercy Gilbert Medical Center — Gilbert, Arizona, United States
Dignity Health-St. Joseph — Phoenix, Arizona, United States
University of Arizona — Tucson, Arizona, United States
University of Arkansas — Little Rock, Arkansas, United States
Cedars-Sinai Heart Institute — Los Angeles, California, United States
UCLA Medical Center — Los Angeles, California, United States
Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center — Torrance, California, United States
Georgetown University — Washington D.C., District of Columbia, United States
Clearwater Cardiovascular Consultants Clinical Research — Clearwater, Florida, United States
South Palm Cardiovascular Research Institute — Delray Beach, Florida, United States
Family Medicine at Eastside Community Practice — Gainesville, Florida, United States
Family Medicine at Hampton Oaks Medical Plaza (Adults and Peds) — Gainesville, Florida, United States
Internal Medicine at Tower Hill — Gainesville, Florida, United States
Family Medicine at Haile Plantation (Adults & Peds) — Gainesville, Florida, United States
Malcom Randall VA Medical Center — Gainesville, Florida, United States
Cardiovascular Clinic at UF Health UF — Gainesville, Florida, United States
Internal Medicine at UF Health Medical Plaza — Gainesville, Florida, United States
Spring Hill Cardiology — Gainesville, Florida, United States
Family Medicine at 4th Ave — Gainesville, Florida, United States
Family Medicine at Old Town (Adults and Peds) — Gainesville, Florida, United States
Baptist Health — Jacksonville, Florida, United States
University of Florida, Jacksonville — Jacksonville, Florida, United States
Naval Hospital Jacksonville — Jacksonville, Florida, United States
Mayo Clinic Jacksonville — Jacksonville, Florida, United States
Cardiology Associates of Mobile, Inc. — Mobile, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.